Literature DB >> 2535647

The role of automated record linkage in the postmarketing surveillance of drug safety: a critique.

S Shapiro1.   

Abstract

Mesh：

Year:  1989        PMID： 2535647     DOI： 10.1038/clpt.1989.154

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  10 in total

Review 1.  Use of routine healthcare data in safe and cost-effective drug use.

Authors:  C J Currie; T M MacDonald
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

Review 2.  Case-population studies in pharmacoepidemiology.

Authors:  Dolors Capellà; Consuelo Pedrós; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Measuring the frequency of adverse drug reactions.

Authors:  P C Waller
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 4.  Pharmacoepidemiology in practice. Current status and future trends.

Authors:  A Alvarez-Requejo; M Porta
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

Review 5.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Ineffectiveness of lipid-lowering therapy in primary care.

Authors:  E Van Ganse; T Souchet; L Laforest; P Moulin; M Bertrand; P Le Jeunne; N Travier; D Yin; E Alemao; G de Pouvourville
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

7.  Post-marketing surveillance of quinolones 1988-1990.

Authors:  P G Davey; T McDonald; G Lindsay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

8.  A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency.

Authors:  J E Ashbury; L E Lévesque; P A Beck; K J Aronson
Journal:  BMC Med       Date:  2010-12-22       Impact factor: 8.775

9.  Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?

Authors:  Akiyuki Suzuki; Hitoshi Sato; Yasutsuna Sasaki
Journal:  Clin Transl Sci       Date:  2019-06-06       Impact factor: 4.689

10.  Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer.

Authors:  Janet E Ashbury; Linda E Lévesque; Patricia A Beck; Kristan J Aronson
Journal:  Front Oncol       Date:  2012-12-05       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.